Remove Disease Remove Molecular Biology Remove RNA
article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

But as molecular biology has advanced, so too has our approach to finding new drugs. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. This method was more about serendipity than science.

article thumbnail

Battling antibiotic resistance in the lab and the clinic

Broad Institute

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections. A combined MD/PhD program offered both opportunities.

Hospitals 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A target for potential cancer drugs may, in fact, worsen disease

The Pharma Data

By creating genetically finagled mouse models and doing single cell RNA-sequencing, Feng and associates plant that Shp2 was needed by excrescence cells for HCC development, which validated and corroborated allowing that Shp2 presented an ideal target for new cancer curatives.

Disease 52
article thumbnail

F. William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines

Broad Institute

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines The groundbreaking, scalable technology is widely used in laboratories around the world today to efficiently produce large amounts of protein and RNA. Merkin (left) and F.

Vaccine 64
article thumbnail

A Look Back

Dark Matter Blog

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA.

article thumbnail

Women in Stem August: Meet Theonie Anastassiadis

Drug Target Review

The implication of this work is that we have an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation, enabling us to provide medicines to patients, especially those with rare or ultra-rare diseases, with no or limited treatment options.

Science 98
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. Having a combination of computational skills & scientific knowledge such as molecular biology, genomics is also important.